GlassScriptPhysician profile
Diane M Settles
NPI 1356462154
$4,934.43
in general payments reported to CMS, 2019-2025
30 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $242 · 2021: $376 · 2022: $583 · 2023: $1,155 · 2024: $860 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,043 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,043.01 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,610.70 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $858.39 | 2019-2024 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $386.00 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ironwood Pharmaceuticals, INC | $302.15 | 2019-2025 | Linzess |
| Gilead Sciences, INC. | $269.28 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.67 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $131.05 | 2023-2025 | |
| Novo Nordisk INC | $116.49 | 2019-2025 | Wegovy |
| Boston Scientific Corporation | $109.40 | 2020-2024 | Spyglass, Exalt Model D |
| Olympus America INC. | $100.97 | 2021-2024 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Phathom Pharmaceuticals, INC. | $98.97 | 2024 | Voquezna |
| Pfizer INC. | $71.06 | 2019-2024 | |
| Ucb, INC. | $66.15 | 2019 | |
| Ferring Pharmaceuticals INC. | $62.89 | 2022-2025 | Rebyota |
| Allergan, INC. | $60.15 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $59.05 | 2024 | Tremfya |
| Nestle Healthcare Nutrition INC. | $58.50 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $50.45 | 2019-2023 | Dificid |
| Ardelyx, INC. | $49.86 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $33.55 | 2023 | Dupixent |
| Madrigal Pharmaceuticals | $31.77 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $27.95 | 2019 | |
| Celltrion USA INC. | $21.94 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $20.46 | 2021 | |
| Intercept Pharmaceuticals, INC. | $18.67 | 2025 | |
| Aimmune Therapeutics, INC. | $17.26 | 2024 | |
| Lilly USA, LLC | $16.31 | 2025 | Mounjaro |
| Redhill Biopharma INC. | $14.09 | 2020 | |
| Medtronic USA, INC. | $13.14 | 2019 | |
| Evoke Pharma, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Settles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.